Mariana de Mendonça Melo

Mariana de Mendonça Melo

Auto-generated profile, based on publicly available information

Mariana de Mendonça Melo

Department of Internal Medicine, Section Infectious Diseases, Erasmus University Medical Centre , Rotterdam

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2023 in Science Advances
Verified
Journal Article
Closed access
HPHenrieke A. B. Prins
Henrieke A. B. Prins
RCRaquel Crespo
Raquel Crespo
CLCynthia Lungu
Cynthia Lungu
SRShringar Rao
Shringar Rao
LLLetao Li
Letao Li
Casper RokxCasper Rokx
Casper Rokx
Reactivation of the latent HIV-1 reservoir is a first step toward triggering reservoir decay. Here, we investigated the impact of the BAF complex inhibitor pyrimethamine on the reservoir of people living with HIV-1 (PLWH). Twenty-eight PLWH on suppressive antiretroviral therapy were randomized (1:1:1:1 ratio) to receive pyrimethamine, valproic acid, both, or no intervention for 14 days. The primary end point was change in cell-associated unspliced (CA US) HIV-1 RNA at days 0 and 14. We observed a rapid, modest, and significant increase in (CA US) HIV-1 RNA in response to pyrimethamine exposure, which persisted throughout treatment and follow-up. Valproic acid treatment alone did not increase (CA US) HIV-1 RNA or augment the effect of pyrimethamine. Pyrimethamine treatment did not result in a reduction in the size of the inducible reservoir. These data demonstrate that the licensed drug pyrimethamine can be repurposed as a BAF complex inhibitor to reverse HIV-1 latency in vivo in PLWH, substantiating its potential advancement in clinical studies.

18 June 2025 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
KHKathryn Sietske Hensley
Kathryn Sietske Hensley
Rob A. GrutersRob A. Gruters
Rob A. Gruters
ENEls van Nood
Els van Nood
MMMariana de Mendonça Melo
Mariana de Mendonça Melo
RORonald J Overmars
Ronald J Overmars
JKJeroen van Kampen
Jeroen van Kampen
Background: HIV-2, although less common than HIV-1, exhibits a higher proportion of elite controllers (ECs), who can suppress HIV without antiretroviral therapy (ART), a phenomenon rarely observed in HIV-1. Studying ECs could yield insights into viral control mechanisms and potentially lead to a cure. Methods: We retrospectively characterized a cohort of people with HIV-2 who received care at the Erasmus University Medical Center, Rotterdam, Netherlands. The aim was to identify categories of ECs based on plasma viral loads, CD4+ T-cell count, and responses to ART. Results: Between 1989 and 2023, 52 people with HIV-2 were included, primarily of West African origin (80.8%). Follow-up ranged from 350 cells/mm3 and viral loads <200 copies/mL without use of ART. Four participants progressed to CD4+ T cells 10 years (recontroller). Conclusions: These data highlight relevant trajectories among ECs. Understanding the underlying mechanisms can inform decisions on treatment and contribute to finding a cure for all people with HIV.